Antimicrobiens
Imipenem-Cilastatin

Imipenem-Cilastatin

Medium
N/A
$28/day

Spectrum of Activity

General Information

Multidrug-resistant gram-negative infection of the lower respiratory tract, urinary tract, intra-abdominal, gynecologic, bone and joint, septicemias, endocarditis, and skin; treatment of multiple organism infection in which other agents have an insufficient spectrum of activity or are contraindicated due to toxic potential; therapeutic alternative for treatment of gram-negative sepsis in immunocompromised patients. Has also been used for the treatment of peritonitis in patients with peritoneal catheters

Renal and hepatic function, CBC.

Phlebitis, tachycardia, seizure, rash, GI upset, decrease blood counts, hepatic dysfunction, acute renal failure, cytopenias, bone marrow suppression

May alter cyclosporine levels, cyclosporine may enhance neurotoxic effect.

Ganciclovir/Valganciclovir may increase seizure risk.

Valproic acid - carbapenems decrease valproate levels and may decrease seizure threshold.

Antimicrobial class: carbapenem

Average serum half life: • Prolonged with renal insufficiency (both drugs) Neonates:

  • Imipenem: 1.7-2.4 hours.
    Cilastatin: 3.9-6.3 hours.
  • Infants and children: Imipenem: 1.2 hours
  • Adults, both drugs: 1 hour

Route of Elimination: When imipenem is given with cilastatin, urinary excretion of unchanged imipenem increases to 70%; 70% to 80% of a cilastatin dose is excreted unchanged in the urine